CMS has proposed a policy to close what it says is a loophole that could help drugmakers avoid Medicare negotiations by making small changes to their existing drugs.
CMS has proposed a policy change that clarifies its stance on how products are grouped together for Medicare negotiations.
Under the Inflation Reduction Act, biologics …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Trump administration revisits policy to close Medicare drug price negotiation loophole
CMS proposes permanent framework for Medicare drug price negotiations
CMS tightens oversight of accreditation facilities, limits fee-based consulting
MedPAC offers a look at enrollment hiccups for Medicare beneficiaries
Medicare's GLP-1 Program Looms; Chemicals in Breast Milk; Acromegaly Drug Rejected
Pharmalittle: We're reading about Medicare and obesity drugs, Germany's pricing plans, and more
Germany backs off plan to install variable discount pricing on drugs: report
Novartis doubles down on molecular glue strategy
Trump administration revisits policy to plug Medicare drug price negotiation loophole.
The Trump administration is floating a proposal to establish a permanent framework for Medicare drug price negotiations. | The…
Pharmaceutical companies are trying to prevent Medicare from negotiating discounts for drugs. Their legal challenges have been…
Pharma companies are facing pricing pressure from several directions, including from the U.S. Medicare negotiations
We've been asking Medicare for weeks about the cost of giving seniors $50 obesity drugs.
The negotiation program was created as part of the 2022 Inflation Reduction Act, which capped years of debate over whether the…
